[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:soluble-epidermal-growth-factor-receptor":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Soluble Epidermal Growth Factor Receptor",87,76,[8,16,23,29,36,43,49,55,61,67,73,79,85,91,98,104,110,116,122,128,134,140,146,152,158,165,170,176,182,188,194,200,206,212,218,224,230,236,242,247,253,259,265,271,277,283,289,295,301,307],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06479239","Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:57.572488Z","2026-07-05T05:32:16.755246Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07544992","Locoregional Administration of Genetically Engineered Cells (EGFR\u002FIL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas",[20],"Phase 1","2026-08-26T02:15:22.311223Z","2026-07-05T05:32:16.686026Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07612189","A Phase 1 Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors",[20],"2026-08-26T02:18:42.501841Z","2026-05-29T15:36:40.230911Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06741085","A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain",[33],"Phase 2","2026-08-26T02:18:09.641312Z","2026-05-05T02:43:29.731134Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":41,"content_modified":42},"NCT07100080","Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)",[40],"Phase 2\u002FPhase 3","2026-08-26T02:18:22.309547Z","2026-05-05T02:43:29.701167Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT06046495","A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer",[20],"2026-08-26T02:16:16.995720Z","2026-05-05T02:43:29.671511Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT04486833","Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib",[12],"2026-08-26T02:18:14.396999Z","2026-05-05T02:43:29.662313Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT05588388","Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases",[33],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:29.356266Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06616623","Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer",[20],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:29.199244Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07315113","Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer",[20],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:29.187036Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07538804","A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer",[12],"2026-08-26T02:19:14.560989Z","2026-05-05T02:43:29.185407Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT04590664","Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma",[12],"2026-08-26T02:18:53.782384Z","2026-05-05T02:43:29.153669Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06043817","First-In-Human Study of STX-721\u002FPFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations",[12],"2026-08-26T02:17:55.355429Z","2026-05-05T02:43:29.021992Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":96,"content_modified":97},"NCT05271240","Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM",[95],"Phase 3","2026-08-26T02:17:04.346841Z","2026-05-05T02:43:29.020647Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT05463848","Surgical Pembro +\u002F- Olaparib w TMZ for rGBM",[33],"2026-08-03T03:33:28.152084Z","2026-05-05T02:43:28.879219Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT05456256","A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma",[33],"2026-08-26T02:19:16.454910Z","2026-05-05T02:43:28.856420Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT07343986","Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma",[20],"2026-08-26T02:17:47.813245Z","2026-05-05T02:43:28.826957Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT06014827","Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma",[33],"2026-08-26T02:17:57.117858Z","2026-05-05T02:43:28.795025Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT07476287","Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer",[33],"2026-08-26T02:16:56.877406Z","2026-05-05T02:43:28.676699Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT05168566","Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer",[33],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:28.646788Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT04181060","Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer",[95],"2026-08-26T02:15:29.632183Z","2026-05-05T02:43:28.627464Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT05498428","A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer",[33],"2026-08-26T02:18:29.369233Z","2026-05-05T02:43:28.561037Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT06736379","Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer",[20],"2026-08-26T02:16:16.169331Z","2026-05-05T02:43:28.548931Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT06415487","ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)",[20],"2026-08-26T02:15:43.339060Z","2026-05-05T02:43:28.536177Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":163,"content_modified":164},"NCT06072586","A Phase 0\u002F1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions",[162],"Early Phase 1","2026-08-26T02:17:28.381459Z","2026-05-05T02:43:28.284426Z",{"nct_id":166,"title":167,"phases":168,"status":13,"updated_at":27,"content_modified":169},"NCT06745908","Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In",[95],"2026-05-05T02:43:28.120702Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":174,"content_modified":175},"NCT06868485","A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer",[33],"2026-08-26T02:18:08.005333Z","2026-05-05T02:43:28.116169Z",{"nct_id":177,"title":178,"phases":179,"status":13,"updated_at":180,"content_modified":181},"NCT07405190","Ivonescimab Alone And With Carboplatin\u002FPemetrexed For NSCLC",[33],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:28.115654Z",{"nct_id":183,"title":184,"phases":185,"status":13,"updated_at":186,"content_modified":187},"NCT05681780","Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC",[20],"2026-08-26T02:16:07.529922Z","2026-05-05T02:43:27.992106Z",{"nct_id":189,"title":190,"phases":191,"status":13,"updated_at":192,"content_modified":193},"NCT04410796","Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers",[33],"2026-08-26T02:19:08.084946Z","2026-05-05T02:43:27.964671Z",{"nct_id":195,"title":196,"phases":197,"status":13,"updated_at":198,"content_modified":199},"NCT07323641","Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer",[33],"2026-08-26T02:17:59.904383Z","2026-05-05T02:43:27.415620Z",{"nct_id":201,"title":202,"phases":203,"status":13,"updated_at":204,"content_modified":205},"NCT07049055","A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer",[12],"2026-08-26T02:18:56.409949Z","2026-05-05T02:43:27.292040Z",{"nct_id":207,"title":208,"phases":209,"status":13,"updated_at":210,"content_modified":211},"NCT06225804","A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer",[20],"2026-08-26T02:17:48.768272Z","2026-05-05T02:43:27.261917Z",{"nct_id":213,"title":214,"phases":215,"status":13,"updated_at":216,"content_modified":217},"NCT03191149","Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change",[33],"2026-08-26T02:19:26.493949Z","2026-05-05T02:43:27.170943Z",{"nct_id":219,"title":220,"phases":221,"status":13,"updated_at":222,"content_modified":223},"NCT06699212","A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases",[95],"2026-08-26T02:19:06.150683Z","2026-05-05T02:43:27.037240Z",{"nct_id":225,"title":226,"phases":227,"status":13,"updated_at":228,"content_modified":229},"NCT02861898","Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma",[12],"2026-08-26T02:15:14.574786Z","2026-05-05T02:43:26.987739Z",{"nct_id":231,"title":232,"phases":233,"status":13,"updated_at":234,"content_modified":235},"NCT06816992","ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC",[20],"2026-08-26T02:18:49.989941Z","2026-05-05T02:43:26.983805Z",{"nct_id":237,"title":238,"phases":239,"status":13,"updated_at":240,"content_modified":241},"NCT05541822","To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation",[33],"2026-08-26T02:15:46.655893Z","2026-05-05T02:43:26.749814Z",{"nct_id":243,"title":244,"phases":245,"status":13,"updated_at":53,"content_modified":246},"NCT05394831","A Phase 1\u002F2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC",[12],"2026-05-05T02:43:26.683799Z",{"nct_id":248,"title":249,"phases":250,"status":13,"updated_at":251,"content_modified":252},"NCT06667076","A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",[33],"2026-08-26T02:18:21.216897Z","2026-05-05T02:35:31.900346Z",{"nct_id":254,"title":255,"phases":256,"status":13,"updated_at":257,"content_modified":258},"NCT04412616","ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies",[20],"2026-08-26T02:18:47.742071Z","2026-05-05T02:35:31.759925Z",{"nct_id":260,"title":261,"phases":262,"status":13,"updated_at":263,"content_modified":264},"NCT07209241","Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM",[20],"2026-08-03T01:58:52.019365Z","2026-05-05T02:35:31.748593Z",{"nct_id":266,"title":267,"phases":268,"status":13,"updated_at":269,"content_modified":270},"NCT06414733","HER-2 B Cell Peptide Vaccine",[20],"2026-08-26T02:15:58.452248Z","2026-05-05T02:35:31.723910Z",{"nct_id":272,"title":273,"phases":274,"status":13,"updated_at":275,"content_modified":276},"NCT04762199","MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer",[20],"2026-08-26T02:16:24.135291Z","2026-05-05T02:35:31.711378Z",{"nct_id":278,"title":279,"phases":280,"status":13,"updated_at":281,"content_modified":282},"NCT06616766","A Phase 1\u002F2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946",[12],"2026-08-26T02:18:15.214990Z","2026-05-05T02:35:31.680026Z",{"nct_id":284,"title":285,"phases":286,"status":13,"updated_at":287,"content_modified":288},"NCT06706076","A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and\u002For HER2 Mutations",[12],"2026-08-26T02:19:02.550788Z","2026-05-05T02:35:31.637829Z",{"nct_id":290,"title":291,"phases":292,"status":13,"updated_at":293,"content_modified":294},"NCT05967689","A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.",[33],"2026-08-26T02:15:20.225313Z","2026-05-05T02:35:31.604740Z",{"nct_id":296,"title":297,"phases":298,"status":13,"updated_at":299,"content_modified":300},"NCT07111520","A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)",[12],"2026-08-26T02:15:39.267524Z","2026-04-29T02:57:57.062678Z",{"nct_id":302,"title":303,"phases":304,"status":13,"updated_at":305,"content_modified":306},"NCT04665206","Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors",[12],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:29.217787Z",{"nct_id":308,"title":309,"phases":310,"status":13,"updated_at":311,"content_modified":312},"NCT04981509","Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer",[33],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:28.854522Z"]